AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira.

AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first-line option in combination with Roche's Gazyva (obinutuzumab) as a ...

Key Takeaways AbbVie seeks FDA approval for Venclexta and Calquence combination for untreated CLL, following positive AMPLIFY trial results. The combination regimen showed a 35% reduction in disease ...

Roche co-markets Venclexta in the US with AbbVie, with the latter selling it on its own elsewhere as Venclyxto, and the drug is a key growth product for both companies.

Venclexta/Venclyxto is a key cancer drug in AbbVie’s portfolio. The drug generated revenues of $405 million for AbbVie in the first quarter of 2021, reflecting growth of 24.5% year over year on ...

VENCLYXTO/VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

Venclexta was tested in 106 patients with the abnormality, about 80 percent of whom had their cancer go into remission, at least partially. Those patients are still being followed.

Venclexta/Venclyxto is a small molecule intended to bind and inhibit the BCL-2 protein, a protein that often resists therapies. Through blocking BCL-2, researchers intend for cancer cells to be ...

In April 2016, the U.S. FDA first granted accelerated approval of VENCLEXTA for the treatment of patients with CLL with 17p deletion, as detected by an FDA-approved test, who have received at ...